Case Report

Radiation primed BOOP: A Case report and Review of literature

Anirudh V Nair*, Ramachandran P V**

* Resident, ** Professor and Head, Department of Radiology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.

Corresponding author: Dr Ramachandran P V, Professor and Head of Department, Department of Radiology, AIMS, Kochi. Email: pvramachandran@gmail.com

Case summary:

A 59 year old non-smoker male presented with 2 weeks history of dyspnea, cough with mucopurulent expectoration and associated chest pain for the last 3 days. He was asymptomatic and leading a normal life until 2 years ago, when he was detected to have carcinoma tongue for which he had undergone local resection. Four months ago he had nodal recurrence in neck for which he underwent modified radical neck dissection followed by radiotherapy in another hospital, the details of which were not available. He remained asymptomatic until the present admission. Laboratory and ECG findings were unremarkable at the time of admission.

Chest X-Ray showed perihilar interstitial shadowing and mild volume loss on left side with bilateral small pleural effusions (fig:1). Computerized tomography thorax with HRCT(fig:2-a,b,c,d) was done which showed multiple patchy areas of ground glass opacities with interlobular septal thickening suggestive of crazy paving pattern. Left lung parenchyma showed predominantly consolidation changes. Bilateral small pleural effusions were also noted. The lung parenchymal changes were predominantly in the peribronchial location. Radiological features were consistent with Bronchiolitis Obliterans Organizing Pneumonia (BOOP).

He was started on antibiotics, corticosteroids and other supportive care. A day after admission, his condition deteriorated with altered sensorium, carbon dioxide narcosis and features of cardiac failure. Cardiology consultation lead to a diagnosis of NSTEMI. Due to persistent and worsening CO2 retention he was intubated and ventilated. He had associated acute renal failure and hypotension which was managed with multiple inotropic support. In spite of aggressive antibiotic therapy, inotropic support and mechanical ventilation his general condition continued to deteriorate. 15 days after admission to our hospital, he developed cardiorespiratory arrest and succumbed to the illness.

Fig 1: Chest radiograph PA view, showing perihilar reticular and patchy acinar shadows, mild volume loss on left side and bilateral mild pleural effusion.
Discussion:

Radiation pneumonitis and chronic radiation fibrosis are well recognized complications of thoracic radiotherapy, rarer parenchymal complications being Radiation primed - Bronchiolitis Obliterans Organizing Pneumonia (BOOP) and eosinophilic pneumonia. In a patient who has undergone radiotherapy, the clinical features and radiological pattern will help clinicians to differentiate the pattern of radiation induced lung disease (RILD) from Radiation primed BOOP, and initiate appropriate treatment and follow up.

Radiation induced lung disease (RILD)

Early transient pneumonitic phase of RILD occur about 4 to 12 weeks after completion of radiotherapy. It manifests as ground glass opacities or consolidation in the field of irradiation. The initial features of pneumonitis can disappear if the lung injury is limited. Chronic radiation fibrosis occurs between 6 to 12 months after radiation, there after attaining stability. Radiation fibrosis manifests with linear scarring, volume loss, consolidation and traction bronchiectasis. With progression of radiation-fibrosis the demarcation between normal and irradiated lung parenchyma becomes more evident.

Histologically, early pneumonitis is characterized by acute exudative phase and further continued damage to lung fields results in organizing phase with interstitial infiltration due to mononuclear and inflammatory cells, subsequently leading to chronic or fibrotic phase.

‘Radiation primed BOOP’

Bronchiolitis Obliterans Organizing Pneumonia (BOOP) is a distinct clinical, imaging and pathological entity characterized by intraluminal plugs of granulation tissue within alveolar ducts and surrounding alveoli with variable degree of interstitial and air space infiltration by foamy macrophages and mononuclear cells.

Clinically half of these patients present with influenza-like illness followed by a few months duration of persistent nonproductive cough, effort dyspnea, low-grade pyrexia, malaise and weight loss. Less common symptoms include pleuritic chest pain and hemoptysis.

Radiological manifestation of BOOP includes patchy bilateral air space consolidation, ground glassing with interstitial thickening giving a crazy paving pattern or perilobular opacities. The distribution is along subpleural and peribrochial distribution. Other findings seen include bronchial wall thickening and dilatation in abnormal areas,
small or large nodular opacities, reversed halo sign or atoll sign, pleural effusion, mediastinal lymphadenopathy etc.

Arbetter KR et al 10, in their study concluded that irradiation damages lung tissue even outside the direct treatment field and suggested that an immunologically mediated lymphocytic alveolitis may be responsible for the recurrent migratory organizing pneumonitis. Bruno Crestani et al 11 in their study of tangential irradiation given to patients with carcinoma breast hypothesized that unilateral lung irradiation may ‘prime’ the lung to further damage, resulting in subsequent development of a characteristic radiologic and histological appearance of BOOP. Radiation primed BOOP is a rare yet distinct entity with very few literature study done in the past 19. The incidence of radiation primed BOOP reported in cases of carcinoma breast ranges between 1.8 to 2.5% 12,13.

The exact mechanism of disease progression is unknown. However the current understanding is that an immunological mechanism is thought to be the etiological factor governing disease. Tissue damage as a result of irradiation results in sensitization of auto reactive lymphocytes, which react with pulmonary tissues resulting in histological and radiological appearance of Cryptogenic Organising Pneumonia (idiopathic BOOP) 14. It is also possible that mast-cells could play a role 15. Some studies suggest the possibility of radiotherapy induced gene activation and transcription, cytokine release and fibroblast activation resulting in priming of lung fields 16.

In radiation-primed BOOP treatment with systemic steroids is effective even though relapses are described after withdrawal 17. A rare rapidly progressive form of BOOP is characterized by quick progression of the disease resulting in acute respiratory failure 18. But this type is not reported in radiation primed BOOP so far.

**Conclusion:**

Radiation induced interstitial lung disease is mostly confined to the field of irradiation. However, Radiation primed BOOP although rare, has to be considered when there is a positive history of irradiation near or within the lung fields in persons with normal lungs and there are clinical manifestations and radiological evidence of migratory alveolitis involving bilateral lung fields later on. We postulate that radiation to neck was responsible for priming the lungs to BOOP in our case. Treatment with long term steroids is effective in preventing the progression of radiation primed BOOP with a good prognosis.

**Reference:**

12. Takigawa N, Segawa Y, Saeki T, Kataoka M, Ida M,


---

**Self assessment Quiz Answer**

1. CT shows circumferential thickening of esophageal wall with mucosal irregularity. This with history of dysphagia is highly suggestive of esophageal carcinoma.

2. In a suspected upper GI malignancy diagnostic investigation is upper GI endoscopy which will help to visualize the lesion and take tissue sample from the abnormal area for histopathological examination to clinch the diagnosis.

3. Most common pulmonary complication of esophageal carcinoma is aspiration pneumonia.

4. Some patients with carcinoma esophagus develop clubbing and hypertrophic pulmonary osteoarthropathy.

5. Most common cause for acquired Tracheo esophageal fistula (TEF) is carcinoma of esophagus. All the other conditions can also lead to TEF.

6. Tracheal involvement by cancer can occur in up to 25% of patients with advanced esophageal cancer.

7. Tracheal involvement is more common with cancers of the mid- and upper part of esophagus as this part is close to trachea.

8. Tracheal involvement in esophageal cancer can be detected by CT scan of thorax.

9. Palliation in these patients is with ‘double’ stents, one in the esophagus and one in the trachea.
Radiology Quiz Answer

Tuberous Sclerosis with Lymphangioleiomyomatosis and renal angiomyolipoma.

Discussion

Lymphangioleiomyomatosis (LAM) is an idiopathic interstitial lung disease predominantly affecting women of the child bearing age. Pathologically, LAM is characterised by peribronchial, perivascular, and perilymphatic proliferation of smooth muscle-like cells, resulting in vascular and airway obstruction with cyst formation. Chest roentgenograph shows hyperinflation or preserved lung volumes (in sharp contrast to most other ILDs), reticulonodular shadows and discrete small cysts. HRCT allows better delineation of the cysts, which, in a classical case, are evenly distributed throughout the lungs. The cysts are small and thin walled. Pneumothorax and chylothorax are known to occur. Diagnosis may be confidently made in a case with classical clinical and radiological features, but atypical presentations need lung biopsy.

Tuberous sclerosis (TSC) is an autosomal dominant neurocutaneous disorder belonging to a group of hamartomatous diseases known as the phakomatoses. TSC is characterized by hamartomas of the skin, eye, heart, kidney, and brain. Seizures during childhood and mental retardation occur routinely. The quoted incidence of LAM in ladies with TSC has been variable in medical literature. Although early literature seemed to indicate a lower incidence of 2-3% only, with modern radiologic techniques rates as high as 30-40% have been reported. Renal angiomyolipomas are known to occur in upto 70% of subjects with TSC, the imaging features again being classical. Nervous system lesions including meningiomas and classic skin lesions (shagreen patches, ash leaf macules, adenoma sebaceum etc) occur in TSC.

Summarising, the present subject had tuberous sclerosis complex with pulmonary lymphangioleiomyomatosis and renal angiomyolipoma with acute intraabdominal bleed.

References

GUIDELINES FOR AUTHORS

The merit of the publication lies in its quality and content. Contributions are invited on any aspect of Pulmonary and critical care medicine. Articles are accepted on the basis of significance, scientific perfection and practical applicability. Authors are requested to base their papers on the basis of original work carried out by themselves or their groups. Manuscripts should not be submitted to more than one journal at a time.

All articles are subjected to a peer review process. Each article is assessed blindly by one or more referees depending on the manuscript type and comments sent back to the authors for revision as required. The Editor’s decision is final on accepting or rejecting an article.

The types of articles published in the journal are as follows:
1. Editorials
2. Reports of original research
3. Critical reviews
4. Meta analysis
5. Case reports (series) with discussions
6. Radiology pearls
7. Educational forum
8. Letters to editor

Manuscripts should be submitted by e-mail or CD in MS Word addressed to,

Dr. Suraj K.P.
The Editor-in-Chief, Pulmon,
Additional Professor, Dept. of Pulmonary Medicine,
Govt. Medical College, Kozhikode, Kerala, 673008.
Ph. 9447445135
E mail: drsurajkp@yahoo.com

Requirements for submission of manuscript

Presentation of manuscripts should conform with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see Ann Intern Med 1997;126:36-47).

The manuscript should be accompanied by
1. Covering letter
2. Undertaking by authors
3. Copyright transfer agreement form.

Covering Letter

The covering letter should explain why the paper should be published in the Pulmon. One of the authors could be identified as the corresponding author of the paper, who will bear the responsibility of the contents of the paper. The name, address, and telephone number of the corresponding author should be provided for all future communication related with the publication of the article. The letter should give any additional information that may be helpful to the editor, such as the type of article and whether the author(s) would be willing to meet the cost of reproducing color illustrations.

Undertaking by Author(s)

It is necessary that all the authors give an undertaking (in the format specified by the journal) indicating their consent to be co-authors in the sequence indicated on the title page. Each author should give his or her names as well as the address and designation current at the time the work was done, plus a current address for correspondence including telephone and fax numbers and email address. A senior author may sign the Undertaking by Authors for a junior author who has left the institution and whose whereabouts are not known and take the responsibility. (Format for submission of undertaking is provided at the end of the session.)

Copyright Transfer Agreement

Author(s) will be asked to sign a transfer of copyright agreement, which recognizes the common interest that both journal and author(s) have in the protection of copyright. It will also allow us to tackle copyright infringements ourselves without having to go back to authors each time. (Format for submission of copyright is provided at the end of the session.)

Manuscript

Manuscripts should be presented in as concise a form as possible, typewritten in double space and numbered consecutively. The contents should be arranged in the following order:

Title page, Abstract, Key words, Introduction, Material & Methods, Results, Discussion, Summary, Acknowledgement and References. Abstract, Tables and legends for Figures should be typed on separate sheets and not in continuation of the main text. Figures and Photographs should be presented in JPEG or GIF format.

Title Page

The title page should carry 1) the title of the article, 2) the name by which each author is known, with his or her highest academic degree and institutional affiliation, 3) the name of the department(s) and institution(s) to which the work should be attributed; 4) disclaimers, if any; 5) the name and address of the author responsible for correspondence and to whom requests for reprints should be addressed; 6) source(s) of support in the form of grants, equipment, drugs, or all of these.

Title of the article should be short, continuous (broken or hyphenated titles are not acceptable) and yet sufficiently descriptive and informative so as to be useful in indexing and information retrieval. A short running title not exceeding 6-7 words to be provided at the foot of the title page.

Abstract

All manuscripts should have a structured abstract (not more than 250 words) with subheadings of Background
& objectives, Methods, Results, Interpretation and Conclusions. Abstract should be brief and indicate the scope and significant results of the paper. It should only highlight the principal findings and conclusions so that it can be used by abstracting services without modification. Conclusions and recommendations not found in the text of the articles should not be inserted in the abstract. A set of suitable key words arranged alphabetically may be provided.

Introduction

Introduction should be brief and state precisely the scope of the paper. Review of the literature should be restricted to reasons for undertaking the present study and provide only the most essential background.

Material & Methods

The procedures adopted should be explicitly stated to enable other workers to reproduce the results, if necessary. New methods may be described in sufficient detail and indicating their limitations. While reporting experiments on human subjects and animals, it should be clearly mentioned that procedures followed are in accordance with the ethical standards laid down by the national bodies or organizations of the particular country. Scanned certificate of ethical clearance should be provided along with manuscript manuscripts in relevant context. The drugs and chemicals used should be precisely identified, including generic name(s), dosage(s) and route(s) of administration.

The statistical analysis done and statistical significance of the findings when appropriate should be mentioned. Unless absolutely necessary for a clear understanding of the article, detailed description of statistical treatment may be avoided.

Results

Only such data as are essential for understanding the discussion and main conclusions emerging from the study should be included. The data should be arranged in unified and coherent sequence so that the report develops clearly and logically. Data presented in tables and figures should not be repeated in the text. Only important observations need to be emphasized or summarised. The same data should not be presented both in tabular and graphic forms. Interpretation of the data should be taken only under the Discussion and not under Results.

Discussion

The discussion should deal with the interpretation of results without repeating information already presented under Results. It should relate new findings to the known ones and include logical deductions. It should also mention any weaknesses of the study.

Summary and conclusions

The summary should provide a brief account of most the relevant observations and conclusions based on the observed data only. This should be linked with the objectives of the study. Statements and conclusions not supported by the data should be avoided. Claims of ongoing studies should also be avoided.

Acknowledgment

Acknowledgment should be brief and made for specific scientific/technical assistance and financial support only and not for providing routine departmental facilities and encouragement or for help in the preparation of the manuscripts (including typing or secretarial assistance).

References

References should be typed on separate page after the text. The total number of References should normally be restricted to a maximum of 30. They should be numbered consecutively in the order in which they are first mentioned in the text. In the text they should be indicated above the line (superior). As far as possible avoid mentioning names of author(s) in the text. Identify references in text, tables, and legends by Arabic numerals in parentheses. References cited only in tables or figure or legends should be numbered in accordance with the sequence in which they appear in the manuscript.

Style of citing references

Use the style of the examples below. The titles of journals should be abbreviated according to the style used in Index Medicus. Avoid using abstracts as references. References of papers accepted but not yet published should be designated as ? in press or ? forthcoming. Authors should obtain written permission to cite such papers as well as verification that they have been accepted for publication. Information from manuscripts submitted but not accepted should be cited in the text as ? unpublished observations with written permission from the source.

Avoid citing a personal communication, unless it provides essential information not available from a public source, in which case the name of the person and date of communication should be cited in parentheses in the text. For scientific articles, authors should obtain written permission and confirmation of accuracy from the source of a personal communication. Please refer http://wwwicmje.org for further details.

All references must be verified by the author(s) against the original documents.

1. Standard Journal article

List the first six authors followed by et al. The usual style is surname followed by initials as shown below


2. Organization as author


3. Books and other Monographs

4. Editor(s), compiler(s) as author

5. Chapter in a book

6. Unpublished Material In press

7. Journal article in electronic format

Tables
Type each table with double spacing on a separate sheet of paper. Do not submit tables as photographs. Number the tables consecutively (in Arabic numerals) in the order of their first citation in the text and supply a brief title for each. Give each column a short or abbreviated heading. Place explanatory matter as footnotes, and not in the heading. For footnotes use the following symbols, in this sequence: *, t, ~, §, II, ~[. **, tt, ~~. Explain in footnotes all abbreviations that are used in each table.

Illustrations (Figures)
Figures should be either professionally drawn and photographed, or submitted as photographic-quality digital prints. For x-ray films, scans, and other diagnostic images, as well as pictures of pathology specimens or photomicrographs, send sharp, glossy, black-and-white or color photographic prints, usually 127 x 173 mm (5 x 7 inches).

Letters, numbers, and symbols on figures should be clear and consistent throughout, and large enough to remain legible when the figure is reduced for publication. Photomicrographs should have internal scale markers.

Symbols, arrows, or letters used in photomicrographs should contrast with the background.

Figures should be numbered consecutively according to the order in which they have been cited in the text. Titles and explanations should be provided in the legend, not on the illustrations themselves. Each figure should have a label pasted on its back indicating the number of the figure and the running title. Do not write on the back of figures, scratch, or mark them by using paper clips.

Legends for Illustrations (Figures)
Type or print out legends for illustrations using double spacing, starting on a separate page, with Arabic numerals corresponding to the illustrations. When symbols, arrows, numbers, or letters are used to identify parts of the illustrations, identify and explain each one clearly in the legend. Explain the internal scale and identify the method of staining in photomicrographs.

If a figure has been published previously, acknowledge the original source and submit written permission from the copyright holder to reproduce the figure. Photographs of potentially identifiable people must be accompanied by written permission to use the photograph.

Color printing requires additional cost that will be communicated to the author.

An electronic version of the figures in JPEG or GIF should be provided for web version. The authors should review the images of such files on a computer screen before submitting them to be sure they meet their own quality standards.

Units of Measurements
Measurements of length, height, weight, and volume should be reported in metric units (meter, kilogram, or liter) or their decimal multiples. Temperatures should be given in degrees Celsius. Blood pressures should be given in millimeters of mercury. All hematologic and clinical chemistry measurements should be reported in the metric system in terms of the International System of Units (SI). Editors may request that alternative or non-SI units be added by the authors before publication.

Abbreviations and Symbols
Use only standard abbreviations. Avoid abbreviations in the title and abstract. The full term for which an abbreviation stands should precede its first use in the text unless it is a standard unit of measurements.

Proofs and reprints
Authors of accepted articles are supplied printer's proofs either by post or through e-mail. Corrections on the proof should be restricted to printer's errors only and no substantial additions/deletions should be made. No change in the names of the authors is permissible at the proof stage. Reprints up to 10 would be supplied as per request of the corresponding author.
UNDERTAKING BY AUTHORS

We, the undersigned, give an undertaking to the following effect with regard to our article entitled “...........................
.............................................................................................................” submitted for publication in Pulmon, the journal of Respiratory Sciences.

1. The article mentioned above has not been published or submitted to or accepted for publication in any form, in any other journal.

2. We also vouchsafe that the authorship of this article will not be contested by anyone whose name(s) is/are not listed by us here.

3. I/We declare that I/We contributed significantly towards the research study i.e., (a) conception, design and/or analysis and interpretation of data and to (b) drafting the article or revising it critically for important intellectual content and on (c) final approval of the version to be published.

4. I/We hereby acknowledge the journal’s conflict of interest policy requirement to scrupulously avoid direct and indirect conflicts of interest and, accordingly, hereby agree to promptly inform the editor or editor’s designee of any business, commercial, or other proprietary support, relationships, or interests that I/We may have which relate directly or indirectly to the subject of the work.

5. I/We also agree to the authorship of the article in the following sequence:-

<table>
<thead>
<tr>
<th>Authors’ Names (in sequence)</th>
<th>Signature of Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. ..............................................................</td>
<td>..............................................................</td>
</tr>
<tr>
<td>2. ..............................................................</td>
<td>..............................................................</td>
</tr>
<tr>
<td>3. ..............................................................</td>
<td>..............................................................</td>
</tr>
<tr>
<td>4. ..............................................................</td>
<td>..............................................................</td>
</tr>
<tr>
<td>5. ..............................................................</td>
<td>..............................................................</td>
</tr>
<tr>
<td>6. ..............................................................</td>
<td>..............................................................</td>
</tr>
<tr>
<td>7. ..............................................................</td>
<td>..............................................................</td>
</tr>
<tr>
<td>8. ..............................................................</td>
<td>..............................................................</td>
</tr>
</tbody>
</table>
COPYRIGHT TRANSFER AGREEMENT

Pulmon, the Journal of Respiratory Sciences is published in 3 issues a year by the Academy of Pulmonary and Critical Care Medicine.

The Pulmon and Authors hereby agree as follows: In consideration of Pulmon reviewing and editing the following described work for first publication on an exclusive basis:

Title of manuscript: .................................................................

The undersigned author(s) hereby assigns, conveys, and otherwise transfers all rights, title, interest, and copyright ownership of said work for publication. Work includes the material submitted for publication and any other related material submitted to Pulmon. In the event that Pulmon does not publish said work, the author(s) will be so notified and all rights assigned hereunder will revert to the author(s).

The assignment of rights to Pulmon includes but is not expressly limited to rights to edit, publish, reproduce, distribute copies, include in indexes or search databases in print, electronic, or other media, whether or not in use at the time of execution of this agreement, and claim copyright in said work throughout the world for the full duration of the copyright and any renewals or extensions thereof.

All accepted works become the property of Pulmon and may not be published elsewhere without prior written permission from Pulmon. The author(s) hereby represents and warrants that they are sole author(s) of the work, that all authors have participated in and agree with the content and conclusions of the work, that the work is original, and does not infringe upon any copyright, propriety, or personal right of any third party, and that no part of it nor any work based on substantially similar data has been submitted to another publication.

Authors’ Names (in sequence)                              Signature of Authors
1. ............................................................................................ ................................ .............................................. ...........................................................
2. ............................................................................................ ................................ .............................................. ...........................................................
3. ............................................................................................ ................................ .............................................. ...........................................................
4. ............................................................................................ ................................ .............................................. ...........................................................
5. ............................................................................................ ................................ .............................................. ...........................................................
6. ............................................................................................ ................................ .............................................. ...........................................................
7. ............................................................................................ ................................ .............................................. ...........................................................
8. ............................................................................................ ................................ .............................................. ...........................................................
The most promising triple therapy in COPD

**Trimium**

Formoterol 6 mcg + Tiotropium 9 mcg + Ciclesonide 200 mcg HFA Inhaler

The Single Inhaler in COPD

Achieve all desired results

Better symptom relief

Greater effect on FEV₁ & inspiratory capacity

Reduction in exacerbation

24% low risk of COPD exacerbation

Better quality of life

Better effect of complementary mode of action on airway caliber by LAMA & ICS/LABA

Favourable tolerability profile

Triple therapy in COPD is well tolerated